Data / New clinical trials / Urinary Bladder Neoplasms

Urinary Bladder Neoplasms trials: 233 new since Nov 2024

Name: New Urinary Bladder Neoplasms clinical trials
Creator: SpecStream
License: https://creativecommons.org/licenses/by/4.0/

The full list. New Urinary Bladder Neoplasms clinical trials: 233 rows for $11.65, first posted on ClinicalTrials.gov from November 12, 2024 to November 9, 2026. The list gains about 9 rows a month. The new rows come each week by email, $19 a month.

Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, enrollment type, location countries and 5 more), which open on your screen as soon as the payment clears and come by email. The weekly rows run until you cancel, from the link in each delivery. The rows on this page are a sample.

For agents and scripts: this list is ordered at https://specstream.ai/data/clinical-trials/condition/urinary-bladder-neoplasms, and every list with its row count and price is at https://specstream.ai/data/lists.json.

Updated November 9, 2026. Source: ClinicalTrials.gov API v2 (U.S. National Library of Medicine).

233 clinical studies in Urinary Bladder Neoplasms were first posted on ClinicalTrials.gov from November 14, 2024 to November 9, 2026; 53 have an industry sponsor and 187 are recruiting or about to. The newest, NCT07924046, was posted on November 9, 2026: Diagnostic Performance of Multiparametric Magnetic Resonance Imaging After Transurethral Resection of Bladder... (University of Lausanne Hospitals).

The request: Every new Urinary Bladder Neoplasms clinical trial on ClinicalTrials.gov, with the sponsor, phase, sites and the listed contact. $10 of credit on sign-up, no card.

Get new trials like these Watch a sponsor

SpecStream is the live web data engine for teams and agents. It reads every new study on ClinicalTrials.gov each morning, and this page is that reading. Ask for the conditions, phases or countries you follow and each new trial arrives in your sheet, CRM, Slack or agent with the sponsor, the sites and the listed contact.

233New trials
53Industry sponsored
187Recruiting or not yet
November 9, 2026Latest posted

Newest trials

The newest 100 of 233, each linked to its record. The full list holds every one with the sponsor class, interventions, start date and the central contact as the record prints it.

First posted	NCT ID	Title	Sponsor	Phase	Status	Conditions	Enrollment	Countries	Source
November 9, 2026	NCT07924046	Diagnostic Performance of Multiparametric Magnetic Resonance Imaging After Transurethral Resection of Bladder Tumour for Prediction of...	University of Lausanne Hospitals	Not applicable	Not yet recruiting	Urinary Bladder Cancer, NMIBC, TURBT, Vi-Rads	86		clinicaltrials.gov
November 3, 2026	NCT07914101	Sequential Chemotherapy Followed by Ultrahypofractionated Radiotherapy for Muscle-Invasive Bladder Cancer	Assiut University	Phase 3	Not yet recruiting	Bladder Cancer, TURBT, Radiotherapy	71		clinicaltrials.gov
November 3, 2026	NCT07912034	EHR Integrated Remote Patient Monitoring to Reduce Readmission for Patients With Bladder Cancer Undergoing Cystectomy	University of Michigan Rogel Cancer Center	Not applicable	Not yet recruiting	Bladder Carcinoma	50	United States	clinicaltrials.gov
November 2, 2026	NCT07908979	Risk-Enabled Therapy After Initiating EV/Pembro for Bladder Cancer	Fox Chase Cancer Center	Phase 2	Recruiting	Bladder Cancer, Urothelial Carcinoma, Muscle-Invasive Bladder Carcinoma, Muscle-invasive Bladder Urothelial Carcinoma	70	United States	clinicaltrials.gov
November 2, 2026	NCT07908407	Remote Screening and Navigation to Increase Trial Enrollment, INVITE Trial	Fred Hutchinson Cancer Center	Not applicable	Not yet recruiting	Bladder Carcinoma, Prostate Carcinoma	50	United States	clinicaltrials.gov
October 30, 2026	NCT07907575	The Role of ERBT Plus Adjuvant Intravesical Induction and Maintenance Chemotherapy for Intermediate-Risk NMIBC	Chinese University of Hong Kong	Not applicable	Not yet recruiting	Bladder Cancer	440	Hong Kong	clinicaltrials.gov
October 27, 2026	NCT07897669	A Real-world Study to Learn About of the Characteristics and Outcomes of Advanced or Metastatic Bladder Cancer Patients With Different...	Pfizer	Observational	Not yet recruiting	Metastatic Urothelial Carcinoma, Urothelial Cancer, Urothelial Carcinoma, Locally Advanced or Metastatic Urothelial...	5,122		clinicaltrials.gov
October 26, 2026	NCT07893509	Outcomes for IR and High Risk (HR) Non-muscle Invasive Bladder Cancer (NMIBC) and ctDNA-based Biomarkers for Response and Recurrence in...	Bladder Cancer Advocacy Network	Observational	Not yet recruiting	NMIBC, MIBC, Muscle Invasive Bladder Cancer (MIBC), Non Muscle Invasive Bladder Cancer	1,400	United States	clinicaltrials.gov
October 22, 2026	NCT07888374	Urinary Cell-Free DNA Liquid Biopsy for Urothelial Cancer Diagnosis and Origin Identification	Ruijin Hospital	Observational	Recruiting	Urothelial Carcinoma (UC), Upper Tract Urothelial Carcinoma, Bladder Cancer	477	China	clinicaltrials.gov
October 19, 2026	NCT07881666	Inactivated UPEC-FimON for Non Muscle Invasive Bladder Cancer After BCG or Intravesical Chemotherapy Failure	Hopec Pharma	Phase 1	Recruiting	Urinary Bladder Neoplasms	30	Israel	clinicaltrials.gov
October 14, 2026	NCT07873333	The Role of Definitive Radiotherapy in Non Muscle Invasive Bladder Cancer	Assiut University	Not applicable	Not yet recruiting	Non Muscle Invasive Bladder Cancer	70		clinicaltrials.gov
October 13, 2026	NCT07869836	BL-M07D1 (Trastuzumab Brengitecan T-bren) vs Standard of Care Platinum-based Chemotherapy (PBC) for HER2-expressing Metastatic Urothelial...	SystImmune Inc.	Phase 3	Recruiting	Urothelial Cancer, Metastatic Urothelial Cancer, Bladder Cancer, Bladder Cancer (BC), Bladder (Urothelial, Transitional...	520	United States	clinicaltrials.gov
October 1, 2026	NCT07853053	DV Plus Toripalimab With Cetirizine and Mecobalamin Pretreatment in Patients With Locally Advanced Unresectable or Metastatic Bladder Cancer	Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University	Phase 1	Not yet recruiting	Bladder Cancer	20	China	clinicaltrials.gov
September 30, 2026	NCT07848854	Trop2-Targeted NIR-II Fluorescent Probe for Identifying Bladder Cancer in Ex Vivo Bladder Samples	Yunnan Cancer Hospital	Phase 2	Recruiting	Bladder Cancer (BC), Urothelial Carcinoma (UC)	30	China	clinicaltrials.gov
September 21, 2026	NCT07829783	A Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) and Pembrolizumab (MK-3475A) in Participants With Bladder Cancer...	Merck Sharp & Dohme LLC	Phase 3	Recruiting	Bladder Cancer	400	Taiwan, Ukraine	clinicaltrials.gov
September 18, 2026	NCT07827612	A Study of Vepugratinib (LY3866288) in Adults With Non-Muscle Invasive Bladder Cancer and Upper Tract Urothelial Cancer	Eli Lilly and Company	Phase 2	Not yet recruiting	Urinary Bladder Neoplasms, Urologic Neoplasms, Receptor, Fibroblast Growth Factor, Type 3	161	United States	clinicaltrials.gov
September 15, 2026	NCT07821177	Bladder Preservation or Cystectomy for MIBC	Dana-Farber Cancer Institute	Early phase 1	Active not recruiting	Muscle-Invasive Bladder Carcinoma, Bladder Cancer, Urothelial Carcinoma	20	United States	clinicaltrials.gov
September 15, 2026	NCT07820566	Development of a Preclinical 3D Vascularized and Perfused Tumoroid Model in Oncology and Urology Developed From Patient Tumors (Kidney...	University Hospital, Strasbourg, France	Observational	Recruiting	Kidney Cancers, Bladder Cancer, Prostate Cancer	100	France	clinicaltrials.gov
September 14, 2026	NCT07817173	Feasibility of HISA During TURBT for NMIBC	CAMC Health System	Not applicable	Not yet recruiting	Bladder Cancer, Bladder (Urothelial, Transitional Cell) Cancer Resectable (Pre-Cystectomy), Non-muscle Invasive Bladder...	40	United States	clinicaltrials.gov
September 8, 2026	NCT07808216	Toripalimab Combined With Intravesical Gemcitabine as Adjuvant Therapy for High-Risk Non-Muscle-Invasive Bladder Cancer After TURBT	Tianjin First Central Hospital	Phase 2	Not yet recruiting	Non Muscle Invasive Bladder Cancer	54		clinicaltrials.gov
September 4, 2026	NCT07804056	A Study to Investigate the Efficacy and Safety of Alpha1H as a Neoadjuvant Therapy in Participants With Low- to Intermediate-Risk/Low-Grade...	Hamlet Pharma AB	Phase 3	Recruiting	Urinary Bladder Neoplasms, Non-muscle Invasive Bladder Cancer (NMIBC)	194	Czechia	clinicaltrials.gov
September 2, 2026	NCT07800507	Trop2-Targeted Near-Infrared Fluorescence Imaging-Guided Precise Resection of Non-Muscle Invasive Bladder Cancer	Yunnan Cancer Hospital	Phase 1/2	Not yet recruiting	NMIBC	30	China	clinicaltrials.gov
September 1, 2026	NCT07798479	Age and Bladder Cancer Outcomes After BCG Treatment: A Multicenter Study	Insel Gruppe AG, University Hospital Bern	Observational	Completed	Bladder Cancer, NMIBC	64		clinicaltrials.gov
August 31, 2026	NCT07795255	Effectiveness of Medical and Environmental Interventions to Reduce Cystoscopy Discomfort (CystoDiscomfort)	Florian Schroeck	Phase 3	Not yet recruiting	Bladder (Urothelial, Transitional Cell) Cancer, Hematuria	1,740	United States	clinicaltrials.gov
August 28, 2026	NCT07793318	TR115 in ARID1A-Mutated Advanced Solid Tumors	Tarapeutics Science Inc.	Phase 2	Not yet recruiting	Ovarian Clear Cell Carcinoma, Endometrial Cancer, Stomach Cancer Recurrent, Urinary Bladder Cancer	50	China	clinicaltrials.gov
August 25, 2026	NCT07784387	A Study to Characterize High-Risk Non-Muscle-Invasive Bladder Cancer Participants in Portugal	Janssen-Cilag Farmaceutica Ltda.	Observational	Recruiting	Urinary Bladder Neoplasms	250	Portugal	clinicaltrials.gov
August 25, 2026	NCT07783815	A Study to Evaluate the Efficacy and Safety of Intravesical Instillation of Disitamab Vedotin Combined With Toripalimab in Patients With...	Xiangya Hospital of Central South University	Phase 1	Not yet recruiting	Bladder Cancer	20	China	clinicaltrials.gov
August 24, 2026	NCT07782164	Irreversible Electroporation (IRE) for Treating Recurrent Pelvic Tumors (PELFIRE Study)	Amsterdam UMC, location VUmc	Observational	Recruiting	Colorectal Carcinoma, Renal Cancer, Bladder Cancer, Cervical Cancer, Prostate Cancer, Ovarian Cancer, Lung Cancer...	27	Netherlands	clinicaltrials.gov
August 24, 2026	NCT07781852	Evaluation of the Distribution of 64Cu/68Ga Labeled CM500 in Healthy Volunteers and Patients With Cancer	Lumina Pharmaceuticals Inc	Early phase 1	Not yet recruiting	Bladder Cancer, Glioma, Glioblastoma (GBM), Breast Cancer, Colorectal Cancer, Esophageal Cancer, Gastric Cancer (GC)...	40	United States	clinicaltrials.gov
August 13, 2026	NCT07762820	REtrieval of Transurethrally Resected Intact En-bloc Vesical Tumors Using a Retrieval Device for Bladder Tumors	Ludwig-Maximilians - University of Munich	Not applicable	Not yet recruiting	Bladder Cancer, Bladder Cancer TNM Staging Primary Tumor (T) T1	75	Denmark, Germany, Greenland	clinicaltrials.gov
August 13, 2026	NCT07762586	Luminal Bladder Cancer Effective Response to Neoadjuvant Chemotherapy (LUMBER-NAC)	Rutgers, The State University of New Jersey	Phase 2	Recruiting	Bladder Cancer	60	United States	clinicaltrials.gov
August 10, 2026	NCT07756008	Bladder-Sparing Treatment With Disitamab Vedotin and Toripalimab With or Without Pelvic Lymph Node Dissection in Bladder Cancer	Tianjin Medical University Second Hospital	Phase 2/3	Not yet recruiting	Bladder Urothelial Carcinoma, Muscle-invasive Bladder Cancer, Bladder Cancer	114	China	clinicaltrials.gov
August 6, 2026	NCT07749924	Active Surveillance Versus Adjuvant Intravesical Chemotherapy in Liquid Biopsy-Defined Low-Shedding Intermediate-Risk NMIBC	Tianjin Medical University Second Hospital	Not applicable	Recruiting	Bladder Cancer, Non-Muscle-Invasive Bladder Cancer (NMIBC)	670	China	clinicaltrials.gov
July 31, 2026	NCT07739121	Benchmarking Large Language Models Against Tumour Boards for Oncology Treatment Recommendations	Assistance Publique - Hôpitaux de Paris	Observational	Recruiting	Breast Neoplasms, Lung Neoplasms, Urologic Neoplasms, Prostatic Neoplasms, Urinary Bladder Neoplasms, Kidney Neoplasms...	100	France	clinicaltrials.gov
July 30, 2026	NCT07735858	Microfluidic Urinary Exosome-Based Diagnostic Model for Bladder Cancer	Cancer Institute and Hospital, Chinese Academy of Medical Sciences	Observational	Active not recruiting	Bladder Cancer	300	China	clinicaltrials.gov
July 30, 2026	NCT07735793	A Real-world Study in Participants With High-risk Non-Muscle-Invasive Bladder Cancer After Bacillus Calmette-Guérin Therapy in Korea	Janssen Korea, Ltd., Korea	Observational	Recruiting	Urinary Bladder Neoplasms	1	South Korea	clinicaltrials.gov
July 29, 2026	NCT07732686	Analysis of Breath Volatile Organic Compounds Using Mass Spectrometry	University of Oklahoma	Observational	Not yet recruiting	Pancreas Cancer, Hepatocellular Carcinoma, Lung Cancer, Ovarian Cancer, Breast Cancer, Head and Neck Cancer, Colon...	2,000	United States	clinicaltrials.gov
July 27, 2026	NCT07728474	LCS103 Herbal Formula for Secondary Prevention of Non-Muscle Invasive Urothelial Carcinoma of the Bladder	LifeBiotic Medical Research Ltd.	Not applicable	Recruiting	Non-muscle Invasive Bladder Cancer (NMIBC)	60	Israel	clinicaltrials.gov
July 27, 2026	NCT07727343	AI-Guided TURBT for Bladder Cancer	Fudan University	Not applicable	Not yet recruiting	Bladder Cancer	170		clinicaltrials.gov
July 24, 2026	NCT07726602	Tumor-informed ctDNA in Muscle-invasive Bladder Cancer for Evaluation of Residual/Recurrent Disease - the TiMBER Trial	OHSU Knight Cancer Institute	Observational	Recruiting	Muscle Invasive Bladder Urothelial Carcinoma, Stage II Bladder Cancer AJCC v8, Stage IIIA Bladder Cancer AJCC v8	100	United States	clinicaltrials.gov
July 24, 2026	NCT07724886	Role of ERBT Plus Intravesical BCG in Intermediate-Risk or High-Risk NMBC	Chinese University of Hong Kong	Not applicable	Recruiting	Bladder Cancer	732	Hong Kong	clinicaltrials.gov
July 23, 2026	NCT07721935	Development of an AI-Agent for Urological Disease Diagnosis and Treatment	Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University	Observational	Recruiting	Urinary Stones, Prostate Cancer, Bladder Cancer	2,000	China	clinicaltrials.gov
July 22, 2026	NCT07720284	An Open-label Study to Investigate the Efficacy and Safety of Dato-DXd + Rilvegostomig vs SoC in Adult Participants With High-risk MIUC	AstraZeneca	Phase 3	Recruiting	High-risk Muscle Invasive Urothelial Carcinoma	915	Australia, Brazil, Canada, China, France, Germany, India, Italy, Japan, Poland...	clinicaltrials.gov
July 21, 2026	NCT07717242	Sun Yat-Sen Treatment Strategy for Enhancing Response in Muscle-invasive Bladder Cancer	Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University	Phase 2	Recruiting	Bladder Urothelial Carcinoma, Bladder Cancer	80	China	clinicaltrials.gov
July 8, 2026	NCT07690878	PTC-guided Neoadjuvant Therapy For Muscle-invasive Bladder Cancer	The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School	Phase 2	Not yet recruiting	Bladder Cancer	35	China	clinicaltrials.gov
June 30, 2026	NCT07675057	Expanded Access for Vepugratinib (LY3866288) in Participants With Fibroblast Growth Factor Receptor 3 (FGFR3) Altered Solid Tumors	Eli Lilly and Company	Not applicable	Available	Urinary Bladder Neoplasms, Neoplasm Metastasis, Carcinoma, Transitional Cell	Not listed		clinicaltrials.gov
June 29, 2026	NCT07673016	Specimen Collection for Validation of UroAmp: A Next Generation Sequencing Platform for Detection and Surveillance of Bladder Cancer	Convergent Genomics, Inc.	Observational	Recruiting	Bladder Cancer, Urothelial Carcinoma (UC), Hematuria, Upper Tract Urothelial Cancer	2,500	Puerto Rico, United States	clinicaltrials.gov
June 25, 2026	NCT07667335	Enfortumab Vedotin, Pembrolizumab and Quemliclustat for the Treatment of Unresectable Locally Advanced and Metastatic Urothelial Cancer	Fred Hutchinson Cancer Center	Phase 1/2	Recruiting	Locally Advanced Bladder Urothelial Carcinoma, Locally Advanced Renal Pelvis Urothelial Carcinoma, Locally Advanced...	27	United States	clinicaltrials.gov
June 24, 2026	NCT07664397	Imaging Study of [89Zr]DFO-YS5 for Cancer Detection	Robert Flavell, MD, PhD	Phase 1	Recruiting	Bladder Cancer, Nerve Sheath Tumor, Nerve Sheath Tumors, Solid Tumor Malignancies, Solid Tumor Cancer, Solid Tumor...	40	United States	clinicaltrials.gov
June 23, 2026	NCT07662863	Sacituzumab Tirumotecan vs MMAE-ADCs in Advanced Urothelial Carcinoma (FUSCC-SPARE-UC-01)	Fudan University	Phase 2	Not yet recruiting	Bladder Cancer, Metastatic Urothelial Carcinoma, Urothelial Carcinoma, Peripheral Neuropathy	75	China	clinicaltrials.gov
June 22, 2026	NCT07660055	Study of [177Lu]Lu-DWJ155 and [68Ga]Ga-DWJ155 in Patients With Solid Tumors	Novartis Pharmaceuticals	Phase 1	Recruiting	Breast Cancer, Non-small Cell Lung Cancer (NSCLC), Gastric/Gastroesophageal Junction (GEJ) Cancer, Bladder Cancer	156	Australia, Canada, Japan, United States	clinicaltrials.gov
June 18, 2026	NCT07657299	Predictive Value of E-cadherin, β-catenin and SOX4 in Recurrence and/or Progression of Non-muscle Invasive Urinary Bladder Transitional...	Ain Shams University	Observational	Completed	Bladder Cancer, Bladder Cancer Recurrence	30	Egypt	clinicaltrials.gov
June 17, 2026	NCT07655284	STENT X: a Randomized Trial to Assess Stent-free Radical Cystectomy	Brigham and Women's Hospital	Phase 3	Withdrawn	Bladder Cancer Requiring Cystectomy, Ureteral Stents	0	Brazil, United States	clinicaltrials.gov
June 15, 2026	NCT07646847	A Study of a Side Effects and Resource Navigation Program for People With Cancer	Memorial Sloan Kettering Cancer Center	Not applicable	Recruiting	Kidney Cancer, Bladder Cancer, Breast Cancer, Lung Cancer	200	United States	clinicaltrials.gov
June 11, 2026	NCT07643519	Neoadjuvant Enfortumab Vedotin Plus Pembrolizumab in Muscle-Invasive Bladder Cancer and Upper Tract Urothelial Carcinoma	University of Florida	Phase 2	Not yet recruiting	Urothelial Carcinoma (UC)	39		clinicaltrials.gov
June 10, 2026	NCT07639983	Multi-Omics-Based Phase Ⅱ Trial of Trastuzumab Rezetecan Plus Camrelizumab for Perioperative Therapy in HER2-Positive Muscle-Invasive...	Sheng Tai	Phase 2	Not yet recruiting	Muscle-Invasive Bladder Cancer (MIBC), Urinary Bladder Cancer	44		clinicaltrials.gov
June 10, 2026	NCT07638410	Prehabilitation in High-risk Oncologic Surgery	Fox Chase Cancer Center	Not applicable	Recruiting	Pancreatic Cancer, Colo-rectal Cancer, Gastric Cancer, Esophageal Cancer, Bladder Cancer, Ovarian Cancer, Abdominal...	180	United States	clinicaltrials.gov
May 29, 2026	NCT07614594	Non-invasive Urinary Genomics-Based Risk Assessment for Early Urothelial Carcinoma Diagnosis	Henan Provincial People's Hospital	Observational	Recruiting	Urothelial Carcinoma (UC), Upper Tract Urothelial Carcinoma, UTUC, Bladder Cancer (BC)	800	China	clinicaltrials.gov
May 27, 2026	NCT07608224	HOPE-07-MIBC: Disitamab Vedotin Plus Immunotherapy vs Chemoimmunotherapy in Resectable HER2-Expressing MIBC	West China Hospital	Phase 2/3	Not yet recruiting	Urinary Bladder Neoplasms	240		clinicaltrials.gov
May 22, 2026	NCT07602010	Comparison of CT and MR (VI-RADS) Imaging for Local Bladder Cancer Staging	Oslo University Hospital	Observational	Recruiting	Bladder Cancer, Urothelial Carcinoma (UC), Muscle Invasive Bladder Cancer (MIBC), Non Muscle Invasive Bladder Cancer	150	Norway	clinicaltrials.gov
May 15, 2026	NCT07589413	Association Between Irrigation Fluid Absorption and Perioperative cfDNA Dynamics After TURBT	Zhiping Wang	Observational	Recruiting	Bladder (Urothelial, Transitional Cell) Cancer, Bladder Cancer Recurrence, Progression of Bladder Cancer, Transurethral...	150	China	clinicaltrials.gov
May 12, 2026	NCT07581496	T1G3R-1 Trial: Detectability and Prognostic Value of ctDNA in T1 G3 Bladder Cancer	University Hospital, Basel, Switzerland	Observational	Recruiting	Bladder Cancer	35	Switzerland	clinicaltrials.gov
May 12, 2026	NCT07579195	Consolidative Therapy After EV + Pembrolizumab in Muscle Invasive Bladder Cancer, REINFORCE Trial	University of Washington	Phase 1/2	Recruiting	Muscle Invasive Bladder Carcinoma, Stage III Bladder Cancer AJCC v8, Stage IV Bladder Cancer AJCC v8	12	United States	clinicaltrials.gov
May 5, 2026	NCT07568444	Enhancing Readability of Lay Abstracts and Summaries for Medical Knowledge Using Generative Artificial Intelligence (BRIDGE AI 3)	University of Southern California	Phase 2	Completed	Prostate Cancer (Adenocarcinoma), Bladder Cancer, Kidney Cancers, Testis Cancer	120	United States	clinicaltrials.gov
May 4, 2026	NCT07566156	Enfortumab Vedotin in Combination With Pembrolizumab vs. Concurrent Chemoradiotherapy (cCRT) in People With Muscle Invasive Bladder Cancer...	Astellas Pharma Global Development, Inc.	Phase 3	Recruiting	Urothelial Cancer, Urinary Bladder Neoplasms	390	Canada, South Korea, Taiwan, United States	clinicaltrials.gov
April 29, 2026	NCT07555769	Calcium Electroporation for Urinary Bladder Tumors: A First-in-Human Feasibility, Safety, and Early Response Trial	Juan Luis Vásquez	Phase 1	Recruiting	Bladder Tumors, Bladder Tumor, Urothelial Carcinoma (UC), Urothelial Carcinoma Bladder	20	Denmark	clinicaltrials.gov
April 29, 2026	NCT07555756	An International Multicenter Clinical Study on Application of UroMed AI Doctor Based on Large Language Models	First Affiliated Hospital of Guangxi Medical University	Not applicable	Not yet recruiting	Kidney Calculi, Prostatic Hyperplasia, Urinary Bladder Neoplasms	1,080	China, Vietnam	clinicaltrials.gov
April 23, 2026	NCT07548476	Acupuncture and Exercise for EV-Pembro-Induced Peripheral Neuropathy	Dana-Farber Cancer Institute	Not applicable	Recruiting	Metastatic Bladder Cancer, Peripheral Neuropathy, Advanced Urothelial Cancer, Metastatic Urothelial Cancer, Bladder...	20	United States	clinicaltrials.gov
April 22, 2026	NCT07545694	Study on the Effects of Drugs That Modulate the Endocannabinoid System on Spontaneous and Induced Contractility of the Human Detrusor Muscle	Fondazione Policlinico Universitario Agostino Gemelli IRCCS	Observational	Recruiting	Bladder Cancer	65	Italy	clinicaltrials.gov
April 16, 2026	NCT07534631	Holmium Laser En-Bloc Resection Versus Conventional Transurethral Resection of Bladder Tumors for Treatment of Non-muscle- Invasive Bladder...	Beni-Suef University	Not applicable	Completed	Bladder Tumor (TURBT)	100	Egypt	clinicaltrials.gov
April 14, 2026	NCT07529639	Tumor Budding and T1 Substaging in Urothelial Bladder Cancer	Assiut University	Observational	Not yet recruiting	Urothelial Bladder Carcinoma, Bladder Carcinoma, Non-Muscle-Invasive Bladder Cancer (NMIBC), Muscle-Invasive Bladder...	100		clinicaltrials.gov
April 13, 2026	NCT07525349	Immune-Stromal Landscape in Muscle-Invasive Bladder Cancer	Assiut University	Observational	Not yet recruiting	Muscle-Invasive Bladder Carcinoma, Urothelial Carcinoma (UC), Bladder Cancer, Muscle-Invasive Urothelial Bladder...	100		clinicaltrials.gov
April 13, 2026	NCT07524426	Local Radiotherapy for Urinary Bladder Cancer in Patients Not Eligible for Curative Treatment	Umeå University	Not applicable	Recruiting	Bladder Cancer (BC)	248	Sweden	clinicaltrials.gov
April 7, 2026	NCT07514897	Detecting CREPT in Urine for Bladder Cancer Diagnosis and Monitoring	Cancer Institute and Hospital, Chinese Academy of Medical Sciences	Observational	Recruiting	Bladder Cancer	250	China	clinicaltrials.gov
April 7, 2026	NCT07514143	Bladder EpiCheck Product Development Study	Nucleix Ltd.	Observational	Recruiting	Suspicion of Bladder Cancer, NMIBC Surveillance	1,000	United States	clinicaltrials.gov
April 6, 2026	NCT07511517	BladMetrix Urine Test for Monitoring Recurrence in Non-Muscle Invasive Bladder Cancer	Oslo University Hospital	Observational	Active not recruiting	Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Bladder	500	Norway	clinicaltrials.gov
April 3, 2026	NCT07510685	Closed-System Bladder Irrigation to Reduce Urinary Tract Infections After Endoscopic Urologic Surgery (IRIS Trial)	University of Pisa	Not applicable	Completed	Urinary Tract Infection Bacterial, Benign Prostatic Hyperplasia, Bladder Cancer	240	Italy	clinicaltrials.gov
March 31, 2026	NCT07503795	Outcomes of Definitive Radiotherapy for Bladder Cancer	Sohag University	Observational	Not yet recruiting	Bladder Cancer (BC)	300	Egypt	clinicaltrials.gov
March 27, 2026	NCT07495072	Early vs Delayed Intravesical Blad-Care During BCG Therapy	BLAD-HYA Group	Not applicable	Recruiting	Urinary Bladder Neoplasms, BCG-Induced Cystitis	56	South Korea	clinicaltrials.gov
March 25, 2026	NCT07492628	Dual-Target Nectin-4/HER2 CAR-NK Cells in Advanced Urothelial Carcinoma	Beijing Biotech	Phase 1	Recruiting	Bladder Cancer, Urothelial Carcinoma, Metastatic Urothelial Carcinoma, Locally Advanced Urothelial Carcinoma, Upper...	42	China	clinicaltrials.gov
March 18, 2026	NCT07481123	COMPARISON OF OBTURATOR NERVE BLOCK TECHNIQUES IN TURBT	Yavuz Saygılı	Not applicable	Completed	Bladder Cancer	60	Turkey (Türkiye)	clinicaltrials.gov
March 18, 2026	NCT07480356	Efficacy and Safety of Intravesical TARA-002 Compared With Investigator's Choice of Intravesical Chemotherapy in Participants With...	Protara Therapeutics	Phase 3	Recruiting	Bladder (Urothelial, Transitional Cell) Cancer, Non-Muscle Invasive Bladder Carcinoma, Non-muscle Invasive Bladder...	284	Ukraine, United States	clinicaltrials.gov
March 16, 2026	NCT07475403	Urinary Tumor DNA-Guided Systemic Immunotherapy for Unresectable Very-High-Risk Non-Muscle-Invasive Bladder Cancer	Tianjin Medical University Second Hospital	Phase 2	Recruiting	Bladder Cancer, Liquid Biopsy, Immunotherapy	53	China	clinicaltrials.gov
March 13, 2026	NCT07468838	Feasibility Study of Urinary cfDNA Analysis as a Non-invasive Monitoring Tool in Patients With Prostate or Bladder Cancer	Institut Cancerologie de l'Ouest	Observational	Not yet recruiting	Prostate Cancer, Bladder Cancer	25		clinicaltrials.gov
March 11, 2026	NCT07464145	A Study of NDV-01 (Sustained-release Gemcitabine-docetaxel) in Participants With Non-muscle Invasive Bladder Cancer	Relmada Therapeutics, Inc.	Phase 3	Not yet recruiting	Bladder (Urothelial, Transitional Cell) Cancer, Bladder (Urothelial, Transitional Cell) Cancer Superficial...	393		clinicaltrials.gov
March 11, 2026	NCT07463963	Relevance of the Urine Bacterial Culture Performed Before TransUrethral Resection of the Bladder for Post-operative Febrile Urinary Tract...	Poitiers University Hospital	Not applicable	Recruiting	Bladder Cancer, Transurethral Resection of the Bladder, Urinary Tract Infection Bacterial	2,600	France	clinicaltrials.gov
March 3, 2026	NCT07445451	Magnesium vs. Dexmedetomidine in TURBT Under Spinal Anesthesia	Dr. Lutfi Kirdar Kartal Training and Research Hospital	Not applicable	Completed	Bladder Tumors, Spinal Anesthesia, Postoperative Pain, Magnesium Sulfate, Dexmedetomidine, Hemodynamic and Respiratory...	93	Turkey (Türkiye)	clinicaltrials.gov
February 20, 2026	NCT07424560	Multiplex Mutation Detection Using Mass Spectrometry in Bladder Cancer	Zhilong Dong	Observational	Recruiting	Bladder Cancer, Bladder Cancer Recurrence, Adjuvant Therapy for Bladder Cancer, Progression of Bladder Cancer	400	China	clinicaltrials.gov
February 19, 2026	NCT07421700	Symbiotic-GU-06: A Study to Learn About PF-08634404 Alone or In Combination With Enfortumab Vedotin in Urothelial Cancer	Pfizer	Phase 1/2	Recruiting	Urothelial Cancer, Advanced/Metastatic Urothelial Cancer, Urothelial Carcinoma	132	Australia, China, Japan, Puerto Rico, Spain, United States	clinicaltrials.gov
February 19, 2026	NCT07420517	Dutasteride in Patients With Low Grade Non-muscle Invasive Bladder Cancer	Paul Toren	Phase 2	Recruiting	Bladder Cancer	95	Canada	clinicaltrials.gov
February 19, 2026	NCT07419295	A Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) to Treat Urothelial Cancer (MK-2870-031)	Merck Sharp & Dohme LLC	Phase 3	Recruiting	Bladder Cancer	590	Argentina, Australia, Belgium, Brazil, Canada, China, France, Germany, Greece...	clinicaltrials.gov
February 17, 2026	NCT07414992	A Study of Radiation Therapy and Cemiplimab With or Without Fianlimab In People With Bladder Cancer	Memorial Sloan Kettering Cancer Center	Phase 2	Withdrawn	Bladder Urothelial Carcinoma	0	United States	clinicaltrials.gov
February 17, 2026	NCT07413523	Randomized Trial of stAndard of Care With or Without Metastases-directed Stereotactic Body Radiation Therapy in Patients Affected by...	Istituto Clinico Humanitas	Not applicable	Recruiting	Bladder Cancer, Urothelial Carcinoma (UC), Oligometastasis	44	Italy	clinicaltrials.gov
February 13, 2026	NCT07410676	EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ± Pembrolizumab in Advanced Solid Tumors	Essen Biotech	Phase 1/2	Recruiting	Cancer, Sarcoma, Leukaemia, Breast Cancer (Locally Advanced or Metastatic), Lung Cancer (Diagnosis), Colorectal Cancer...	83	China	clinicaltrials.gov
February 13, 2026	NCT07408830	VA Randomized Trial of Surveillance Intervals After Transurethral Resection of High Grade Bladder Tumors	VA Office of Research and Development	Not applicable	Not yet recruiting	High-Grade Early-Stage Bladder Cancer	2,482	United States	clinicaltrials.gov
February 11, 2026	NCT07403630	INTEGRATIVE "MULTI-OMICS" AND FUNCTIONAL PLATFORM FOR THE COMPLETE DIAGNOSTIC CHARACTERIZATION OF TUMORS: THE ITALIAN TUMOR CHEMOGENOMIC...	Azienda Ospedaliero-Universitaria di Parma	Not applicable	Recruiting	Acute Leukemia, Multiple Myeloma, Squamous Cell Carcinoma, Pleural Mesothelioma, Pancreatic Cancer, Bladder Cancer...	300	Italy	clinicaltrials.gov
February 9, 2026	NCT07395037	A Study of Ward Admissions for Haematuria	British Urology Researchers in Surgical Training	Observational	Recruiting	Urologic Diseases, Hematuria, Hematuria; Benign, Bladder Cancer, Renal Cancer, Urothelial Carcinoma	1,050	United Kingdom	clinicaltrials.gov
February 5, 2026	NCT07391137	CRUCIAL-R Study : Cruciferous Vegetables Dietary Regimen in NMIBC	S. Andrea Hospital	Not applicable	Active not recruiting	Recurrence Free Survival, Bladder Cancer Recurrence	250	Italy	clinicaltrials.gov
January 30, 2026	NCT07379281	Evaluating the Efficacy of Neoadjuvant Chemotherapy Drugs Based on Organoid Technology	Qilu Hospital of Shandong University	Observational	Recruiting	Bladder Cancer	254	China	clinicaltrials.gov
January 30, 2026	NCT07379268	Evaluation of the Efficacy of Anti-HER2 Antibody-Drug Conjugates (ADC) in Locally Advanced or Metastatic Bladder Cancer Based on Organoid...	Qilu Hospital of Shandong University	Observational	Recruiting	Bladder Cancer	224	China	clinicaltrials.gov

Sponsors posting most

Sponsor	New trials	Latest
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University	6	October 1, 2026
Tianjin Medical University Second Hospital	6	August 10, 2026
Assiut University	5	November 3, 2026
Merck Sharp & Dohme LLC	5	September 21, 2026
AstraZeneca	5	July 22, 2026
Mayo Clinic	5	December 16, 2025
Chinese University of Hong Kong	4	October 30, 2026
Pfizer	4	October 27, 2026
University of Washington	4	May 12, 2026
Qilu Hospital of Shandong University	4	January 30, 2026
Yunnan Cancer Hospital	3	September 30, 2026
Eli Lilly and Company	3	September 18, 2026
Rutgers, The State University of New Jersey	3	August 13, 2026
Cancer Institute and Hospital, Chinese Academy of Medical Sciences	3	July 30, 2026
Memorial Sloan Kettering Cancer Center	3	June 15, 2026
Peking University First Hospital	3	August 8, 2025
National Cancer Institute (NCI)	3	July 14, 2025
Fox Chase Cancer Center	2	November 2, 2026
Fred Hutchinson Cancer Center	2	November 2, 2026
Dana-Farber Cancer Institute	2	September 15, 2026

By phase

Phase	New trials	Latest
Not applicable	71	November 9, 2026
Observational	65	October 27, 2026
Phase 2	34	November 2, 2026
Phase 1	23	October 19, 2026
Phase 3	18	November 3, 2026
Phase 1/2	14	September 2, 2026
Phase 2/3	5	August 10, 2026
Early phase 1	2	September 15, 2026
Phase 4	1	January 8, 2025

By country

Country	New trials	Latest
United States	86	November 3, 2026
China	57	October 22, 2026
Italy	21	July 22, 2026
France	18	September 15, 2026
Canada	17	July 22, 2026
Spain	15	July 22, 2026
United Kingdom	13	July 22, 2026
Australia	11	July 22, 2026
Germany	10	August 13, 2026
Turkey (Türkiye)	10	March 18, 2026
Netherlands	9	August 24, 2026
South Korea	9	July 30, 2026
Japan	9	July 22, 2026
Denmark	8	August 13, 2026
Brazil	8	July 22, 2026
Israel	7	October 19, 2026
Egypt	6	June 18, 2026
Taiwan	5	September 21, 2026
Norway	5	May 22, 2026
Sweden	5	April 13, 2026
Belgium	5	February 19, 2026
Hong Kong	4	October 30, 2026
Czechia	4	September 4, 2026
Poland	4	July 22, 2026
Austria	4	October 30, 2025

Where the register publishes

U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Condition groups are the MeSH terms ClinicalTrials.gov assigns to each study's conditions; a study with several is in several groups. Sponsor class is the register's class of the lead sponsor. The central contact is in the full list only as the record prints it. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.